Latham & Watkins represented the underwriters in the transaction. Immunovant, Inc. executed its underwritten public offering of 5,270,093 shares of its common stock at a price…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
